Search Results - "Minamida, Takeshi"
-
1
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
Published in The Lancet infectious diseases (01-04-2024)“…Licensed mRNA COVID-19 vaccines require booster doses to sustain SARS-CoV-2-specific responses, creating the need for novel, broadly immunogenic vaccines. We…”
Get full text
Journal Article -
2
Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2
Published in The Lancet infectious diseases (01-04-2024)“…Despite their high efficacy against the original Wuhan-Hu-1 strain and early SARS-CoV-2 variants, mRNA vaccines elicit a relatively short duration of immunity,…”
Get full text
Journal Article -
3
Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial
Published in The Lancet infectious diseases (23-10-2024)“…We previously showed that ARCT-154, a self-amplifying mRNA COVID-19 vaccine, had improved immunogenicity and antibody persistence compared with conventional…”
Get full text
Journal Article -
4
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine
Published in The Lancet infectious diseases (07-10-2024)Get full text
Journal Article -
5
Physical States of Surface and Core Lipids in Lipid Emulsions and Apolipoprotein Binding to the Emulsion Surface
Published in The Journal of biological chemistry (28-06-1996)“…Plasma triglyceride-rich lipoproteins vary in lipid composition during their metabolism. We investigated the effects of the lipid composition of emulsion…”
Get full text
Journal Article